Tenaya Therapeutics Inc (TNYA) Stock Price, Quote & News

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacet...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 825 6990

Website: www.tenayatherapeutics.com

Address:

171 Oyster Point Boulevard, Suite 500, South San Francisco, United States

Raumerica Apr. 28 at 10:11 PM

$TNYA F off FAKE FUDster! Nobody believes a word you say clown!

1 · Reply

perfecto50 Apr. 28 at 10:03 PM

$TNYA ok clowns, might regret this, big buy on this stock to hold. I hope to hell i was wrong or im screwed

1 · Reply

Raumerica Apr. 28 at 8:06 PM

$TNYA It is haha Spinaroonie! What a pathetic clown: posting under 3 pseudonyms! Did “your family” tell you no results would be posted? That’s why you’re the board joke!

1 · Reply

perfecto50 Apr. 28 at 7:03 PM

$TNYA under 70 again hahah

0 · Reply

Patience4200 Apr. 28 at 4:46 PM

$TNYA

0 · Reply

AutisticRetardo Apr. 28 at 2:39 PM

$TNYA if you're on reddit be aware that user "Boring-Tangerine5166" is probably @Spinaroonie

1 · Reply

Rolfthewild Apr. 28 at 1:48 PM

$TNYA Definitely panic in the streets. This is where it gets interesting and will depend if institutional investors buy it up. It's also a sign that this phase is getting closer to a conclusion. True longs do not worry about the noise but just know the pressure will get tough before the rise.

1 · Reply

Paulfrench Apr. 28 at 6:31 AM

$TNYA I have a feeling things are starting to move slowly. A bullish VSA divergence appeared on yesterday's candle, meaning buyers have begun to absorb the downward pressure. The chart indicates that the price is just below significant resistance levels (50-day moving average, Kijun-sen), and if we manage to break through them, we can try to break above the top of the range, which would be a strong signal to resume the upward trend. Patience is still key, my friends! 🫡

0 · Reply

stock_x_pirate Apr. 27 at 8:02 PM

$TNYA who is selling? large order fullfilled today. It pays to know something about the company to increase conviction. This is going much higher. Enjoy the ride longs.

2 · Reply

AutisticRetardo Apr. 27 at 6:32 PM

$TNYA Alexion/AstraZenica is trying to leapfrog TN-201 and TN-401 with advanced capsids/promoters designed to better target heart tissue so they can say their shots are safer/lower dose. Problem is that TNYA has Oprhan Drug Designation which means if a shot gets approved no one can compete with it for 7 years. They also hold patents that AZ would likely come up against if they followed through with their projects! (WO2020205889A1 & WO2021163357A2) IMHO, this is a bluff! AstraZenica is trying to keep the price of TNYA under control while they try to negotiate a buyout! Keep holding!

1 · Reply

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Mar 11, 2026, 4:05 PM EDT - 6 weeks ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 9, 2026, 1:00 PM EDT - 7 weeks ago

Tenaya Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:30 AM EDT - 7 weeks ago

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

Mar 5, 2026, 1:35 PM EST - 7 weeks ago

Tenaya Therapeutics Stock Jumps After New Alnylam Deal

ALNY

Mar 5, 2026, 9:10 AM EST - 7 weeks ago

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

ALNY

Mar 5, 2026, 8:30 AM EST - 7 weeks ago

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

ALNY

Mar 2, 2026, 4:05 PM EST - 2 months ago

Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

Jan 9, 2026, 8:30 AM EST - 3 months ago

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Dec 12, 2025, 1:56 PM EST - 4 months ago

Tenaya Stock Plunges After $60 Million Equity Offering

Dec 12, 2025, 12:16 AM EST - 4 months ago

Tenaya Therapeutics Announces Pricing of Public Offering

Dec 11, 2025, 5:00 PM EST - 4 months ago

Tenaya Therapeutics Transcript: Study Result

Dec 11, 2025, 4:02 PM EST - 4 months ago

Tenaya Therapeutics Announces Proposed Public Offering

Dec 11, 2025, 4:01 PM EST - 4 months ago

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

Dec 11, 2025, 4:01 PM EST - 4 months ago

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

Nov 10, 2025, 8:00 AM EST - 6 months ago

Tenaya Therapeutics Transcript: Status Update

Nov 8, 2025, 11:25 AM EST - 6 months ago

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Nov 4, 2025, 5:30 PM EST - 6 months ago

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Oct 21, 2025, 12:00 PM EDT - 6 months ago

Tenaya Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Tenaya Therapeutics Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Oct 9, 2025, 4:05 PM EDT - 7 months ago

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Oct 2, 2025, 4:05 PM EDT - 7 months ago

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Sep 18, 2025, 4:05 PM EDT - 7 months ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Sep 9, 2025, 4:50 PM EDT - 8 months ago

Tenaya Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 4:05 PM EDT - 8 months ago

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 31, 2025, 10:15 AM EDT - 8 months ago

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Aug 26, 2025, 11:30 AM EDT - 8 months ago

Tenaya Therapeutics Transcript: KOL Event

Aug 12, 2025, 11:30 AM EDT - 9 months ago

Tenaya Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 8, 2025, 8:00 AM EDT - 9 months ago

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 9 months ago

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:30 AM EDT - 9 months ago

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

May 13, 2025, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Apr 24, 2025, 2:07 PM EDT - 1 year ago

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Mar 12, 2025, 8:40 AM EDT - 1 year ago

Tenaya Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 1:10 PM EST - 1 year ago

Tenaya Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 8:30 AM EST - 1 year ago

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Jan 13, 2025, 9:16 AM EST - 1 year ago

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Transcript: Study Update

Dec 16, 2024, 4:30 PM EST - 1 year ago

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Tenaya Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Jun 27, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics Announces Research Leadership Updates

Jun 21, 2024, 11:20 AM EDT - 2 years ago

Tenaya Therapeutics Transcript: TD Cowen Genetic Medicines & RNA Summit

Jun 18, 2024, 4:30 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

May 14, 2024, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 5:00 PM EDT - 2 years ago

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Mar 18, 2024, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Mar 12, 2024, 8:40 AM EDT - 2 years ago

Tenaya Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Feb 26, 2024, 8:30 AM EST - 2 years ago

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Feb 8, 2024, 8:00 AM EST - 2 years ago

Tenaya Therapeutics Announces Pricing of Underwritten Offering

Jan 11, 2024, 12:45 PM EST - 2 years ago

Tenaya Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 3, 2024, 8:30 AM EST - 2 years ago

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:30 PM EST - 2 years ago

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

Oct 26, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Oct 9, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

Oct 2, 2023, 5:30 PM EDT - 2 years ago

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Sep 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Sep 12, 2023, 2:55 PM EDT - 2 years ago

Tenaya Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Raumerica Apr. 28 at 10:11 PM

$TNYA F off FAKE FUDster! Nobody believes a word you say clown!

1 · Reply

perfecto50 Apr. 28 at 10:03 PM

$TNYA ok clowns, might regret this, big buy on this stock to hold. I hope to hell i was wrong or im screwed

1 · Reply

Raumerica Apr. 28 at 8:06 PM

$TNYA It is haha Spinaroonie! What a pathetic clown: posting under 3 pseudonyms! Did “your family” tell you no results would be posted? That’s why you’re the board joke!

1 · Reply

perfecto50 Apr. 28 at 7:03 PM

$TNYA under 70 again hahah

0 · Reply

Patience4200 Apr. 28 at 4:46 PM

$TNYA

0 · Reply

AutisticRetardo Apr. 28 at 2:39 PM

$TNYA if you're on reddit be aware that user "Boring-Tangerine5166" is probably @Spinaroonie

1 · Reply

Rolfthewild Apr. 28 at 1:48 PM

1 · Reply

Paulfrench Apr. 28 at 6:31 AM

0 · Reply

stock_x_pirate Apr. 27 at 8:02 PM

$TNYA who is selling? large order fullfilled today. It pays to know something about the company to increase conviction. This is going much higher. Enjoy the ride longs.

2 · Reply

AutisticRetardo Apr. 27 at 6:32 PM

1 · Reply

Ommo Apr. 27 at 5:42 PM

$TNYA Hey everyone, just a heads-up! The TN-401 trial data will be presented on Friday, May 15th. Keep an eye out—this could be a big moment!

1 · Reply

Modernnista Apr. 27 at 5:34 PM

$TNYA

0 · Reply

Abzino88 Apr. 27 at 4:12 PM

$TNYA ok let me rephrase- results out in a couple of weeks…. FACT

0 · Reply

Raumerica Apr. 27 at 4:04 PM

$TNYA You’re the POS! We will see Fake FUDster! You are a pathetic clown! The volume is picking up and the price is rising! I can’t wait to revisit your pathetic bashing that fools NOBODY… This is Spinaroonie…

1 · Reply

mansleeping373 Apr. 27 at 3:39 PM

$TNYA Definitely happy to hear they'll be presenting on 401 (their 2nd most advanced study) and that data should be good (again). Don't forget though: 201 is the big dog that's been tested on humans for almost 3 years now (with a larger afflicted population/market)....so there's still more, bigger news to come. I think we should also be looking for updates on the Alnylam partnership within the next couple months.

1 · Reply

Spinaroonie Apr. 27 at 3:33 PM

$TNYA wow news really moved this POS hahah

1 · Reply

Ray89c Apr. 27 at 2:03 PM

$TNYA I guess we will do $1 before earnings as the have strategically placed the presentation of results during same time

1 · Reply

americanpsycho42 Apr. 27 at 1:47 PM

$TNYA climing steady, nice to see, I believe we will hit 1 again between now and may 15

0 · Reply

Ray89c Apr. 27 at 1:46 PM

$TNYA it’s building up I guess. People haven’t realized the news lll

0 · Reply

Ray89c Apr. 27 at 1:37 PM

$TNYA why no price changes with new article ?

1 · Reply

BARG83 Apr. 27 at 1:24 PM

$TNYA 🥳✌️finally

1 · Reply

Raumerica Apr. 27 at 1:14 PM

$TNYA We will see… So Spinaroonie says it’s fluff everybody! Mark this post … The pathetic board clown has spoken! We will revisit over the next three weeks… the price is .68 now… Can’t wait…

1 · Reply

Market Cap	145.87M
Revenue (ttm)	0.00
Net Income (ttm)	-90.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,625,917
Avg Vol	4,287,978
Day's Range	N/A - N/A
Shares Out	217.00M
Stochastic %K	3%
Beta	2.99
Analysts	Strong Sell
Price Target	$9.00